Clinical Trials Sponsored by Optimer Pharmaceuticals LLC

Total 629 results

Optimer Pharmaceuticals LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Clostridium Difficile-associated Diarrhea
Optimer Pharmaceuticals LLC

Completed

Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)

Diarrhea | Clostridium Infections
Optimer Pharmaceuticals LLC

Completed

PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

Diarrhea | Clostridium Infections

United States, France, United Kingdom, Belgium, Spain, Canada, Germany, Italy, Sweden
Optimer Pharmaceuticals LLC

Completed

OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)

Diarrhea

United States
Optimer Pharmaceuticals LLC

Completed

Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001) (DEFLECT-1)

Clostridium Difficile-Associated Diarrhea (CDAD)
Optimer Pharmaceuticals LLC

Completed

Safety and Efficacy of Prulifloxacin vs Placebo in Treatment of Acute Gastroenteritis in Adult Travelers

Acute Bacterial Gastroenteritis

India
Hartford Hospital
Optimer Pharmaceuticals LLC

Completed

Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin

Clostridium Difficile Infection

United States
Boston Medical Center
Cepheid; Optimer Pharmaceuticals LLC

Completed

Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients

Crohn's Disease | Ulcerative Colitis | Inflammatory Bowel Disease | Clostridium Difficile

United States
Optimum Therapeutics, LLC

Terminated

Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
MedDay Pharmaceuticals SA
Eurofins Optimed

Terminated

HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects

Healthy Volunteers | Hepatic Impairment of Moderate Child Pugh Category

France, Hungary
MedDay Pharmaceuticals SA
Eurofins Optimed

Terminated

RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects

Healthy Volunteers | Impaired Renal Function

France, Hungary
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS (OS440-3004)

Multiple Sclerosis | Spasticity, Muscle

Serbia, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Moldova, Republic of, Poland
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
Amneal Pharmaceuticals, LLC
Novum Pharmaceutical Research Services

Completed

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS (OS440-3005)

Multiple Sclerosis | Spasticity, Muscle

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Withdrawn

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Multiple Sclerosis | Sperm

United States
Generica Pharmaceuticals
Optimum Contract Research Organisation

Completed

Efficacy and Safety of NEM® Brand Eggshell Membrane in Patients With Grade 2/3 Knee Osteoarthritis

Osteoarthritis, Knee

Turkey
Saptalis Pharmaceuticals LLC
bioRASI, LLC

Completed

A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies

Scabies

United States
Amneal Pharmaceuticals, LLC
Symbio, LLC

Completed

Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)

Uncomplicated Urinary Tract Infections

United States
Kind Pharmaceuticals LLC

Not yet recruiting

A Study of Safety and Efficiency of AND017 in Patients With Transfusion Dependent and Non-transfusion Dependent β-thalassemia

β -Thalassemia
Kind Pharmaceuticals LLC

Not yet recruiting

A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy

Chemotherapy Induced Anemia
Cali Pharmaceuticals LLC

Recruiting

Herniorrhaphy for Postoperative Pain

Hernia, Inguinal

United States
Hikma Pharmaceuticals LLC

Recruiting

Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia (CARCML)

Chronic Myeloid Leukemia

Egypt
Deciphera Pharmaceuticals LLC

Completed

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumor

United States
Hikma Pharmaceuticals LLC

Completed

Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region

Relapsing Remitting Multiple Sclerosis

Algeria, Egypt, Jordan
Deciphera Pharmaceuticals LLC

Completed

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumor

United States
Salarius Pharmaceuticals, LLC

Enrolling by invitation

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Ewing Sarcoma | Myxoid Liposarcoma | Desmoplastic Small Round Cell Tumor | Angiomatoid Fibrous Histiocytoma | Extraskeletal Myxoid Chondrosarcoma | Clear Cell Sarcoma | Myoepithelial Tumor | Sclerosing Epithelioid Fibrosarcoma | Low Grade Fibromyxoid Sarcoma

United States
Deciphera Pharmaceuticals LLC

Completed

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (INVICTUS)

Gastrointestinal Stromal Tumors

United States, France, Finland, United Kingdom, Germany, Netherlands, Italy, Belgium, Spain, Canada, Australia, Poland, Singapore
Cali Pharmaceuticals LLC

Completed

Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in the Management of Acute Postoperative Pain

Abdominoplasty

United States
Cubist Pharmaceuticals LLC

Completed

A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)

Clostridium Difficile Infection
Thetis Pharmaceuticals LLC

Completed

PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA

Hypertriglyceridemia | Diabetes Mellitus, Non-Insulin-Dependent

United States
Deciphera Pharmaceuticals LLC

Withdrawn

Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumors
Hikma Pharmaceuticals LLC

Completed

Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients

Inflammatory Bowel Diseases | Crohn Disease | Ulcerative Colitis | Fistulizing Crohn's Disease

Saudi Arabia
Curatek Pharmaceuticals, LLC

Completed

Multi-Center Study of New Medications to Treat Vaginal Infections (SMART GIVES)

Vaginal Infection

United States
Cubist Pharmaceuticals LLC

Completed

Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008) (ASPECT-NP)

Lung Diseases | Healthcare-Associated Pneumonia | Ventilator-Associated Pneumonia
Cubist Pharmaceuticals LLC

Completed

Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics

Gram-positive Bacterial Infections

United States
Cubist Pharmaceuticals LLC

Completed

Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia

Pneumonia, Bacterial
Cubist Pharmaceuticals LLC

Completed

Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae

Pneumonia, Bacterial
Cubist Pharmaceuticals LLC

Completed

Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics

Gram Positive Bacterial Infection

United States
Sephoris Pharmaceuticals LLC

Terminated

Clinical Trial of the Safety and Efficacy of SP160412 in the Temporary Relief of Mild to Moderate Sunburn

Sunburn

Mauritius
Cubist Pharmaceuticals LLC

Completed

Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)

Proven or Suspected Gram-negative Bacterial Infection | Peri-operative Prophylaxis
Cubist Pharmaceuticals LLC

Completed

Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)

Skin Diseases, Infectious | Skin Diseases, Bacterial
Cubist Pharmaceuticals LLC

Completed

Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)

Clostridium Difficile Infection
Shenox Pharmaceuticals, LLC

Unknown

Ketamine for Major Depressive Disorder

Major Depressive Disorder

United States
Cubist Pharmaceuticals LLC

Terminated

Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia (HDSAB)

Infective Endocarditis | Endocarditis, Bacterial

United States
Cubist Pharmaceuticals LLC

Terminated

Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

Opioid-Induced Constipation
Cubist Pharmaceuticals LLC

Completed

Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA (DAPHEOR1006)

Staphylococcal Skin Infections

United States, Puerto Rico
Cubist Pharmaceuticals LLC

Terminated

Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment (RENSE)

Renal Impairment | Complicated Skin and Skin Structure Infections | S. Aureus Bacteremia

United States
MSD Pharmaceuticals LLC

Unknown

Clinical and Radiological Manifestations of Coxitis in Patients With Ankylosing Spondylitis Treated With Golimumab (GO-COX)

Ankylosing Spondylitis | Coxitis

Russian Federation

3

Subscribe